<DOC>
	<DOCNO>NCT00773188</DOCNO>
	<brief_summary>This single arm study ass feasibility use , safety tolerability Avastin ( bevacizumab ) combination chemoradiation therapy patient locally advance unresectable non-squamous non-small cell lung cancer.An initial cohort patient receive Avastin 7.5mg/kg iv every 3 week , combination concurrent thoracic radiation 6.6 week chemotherapy ( cisplatin 75 mg/m2 iv vinorelbine 15mg/m2 iv administer accord standard treatment protocol ) . If dose-limiting toxicity observe , second cohort patient receive Avastin dose 15mg/kg iv every 3 week , combination similar treatment regimen first cohort . After 5 cycle combination treatment , Avastin monotherapy administer 4 cycle . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Feasibility Trial Avastin ( Bevacizumab ) Combination With Concomitant Chemoradiation ( Cisplatin Vinorelbine ) Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>patient &gt; =18 year locoregional advance unresectable nonsquamous NSCLC ; ECOG performance status 0 1 ; prior thoracic head neck irradiation surgical resection current lung cancer . mixed , nonsmall cell small cell tumor ; mixed adenosquamous carcinoma predominant squamous component ; evidence tumor invasion encasement major vessel ; history grade &gt; =2 hemoptysis ; presence cavitations lung lesion baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>